SEC Form 4 · accession 0001797826-26-000002
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy Thornberry
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 3, 2026 | A | 6,408 | $0.00 | A | 31,125 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $19.66 | Jun 3, 2026 | A | 19,226 | A | — | Jun 3, 2036 | Common Stock | 19,226 | 19,226 | D |
Explanation of responses
- F1Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2Includes 6,408 unvested RSUs.
- F3100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.